1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice - PubMed (original) (raw)
. 2005 Apr;146(4):1956-64.
doi: 10.1210/en.2004-1322. Epub 2005 Jan 6.
Affiliations
- PMID: 15637289
- DOI: 10.1210/en.2004-1322
1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice
Conny A Gysemans et al. Endocrinology. 2005 Apr.
Abstract
1,25-Dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is an immune modulator that prevents experimental autoimmune diseases. Receptors for 1,25-(OH)(2)D(3) are present in pancreatic beta-cells, the target of an autoimmune assault in nonobese diabetic (NOD) mice. The aim of this study was to investigate the in vivo and in vitro effects of 1,25-(OH)(2)D(3) on beta-cell gene expression and death and correlate these findings to in vivo diabetes development in NOD mice. When female NOD mice were treated with 1,25-(OH)(2)D(3) (5 microg/kg per 2 d), there was a decrease in islet cytokine and chemokine expression, which was accompanied by less insulitis. Complementing these findings, we observed that exposure to 1,25-(OH)(2)D(3) in three cell systems INS-1(E) cell line, fluorescence-activated cell sorting purified rat beta-cells, and NOD-severe combined immunodeficient islets) suppressed IP-10 and IL-15 expression in the beta-cell itself but did not prevent cytokine-induced beta-cell death. This 1,25-(OH)(2)D(3)-induced inhibition of chemokine expression in beta-cells was associated with a decreased diabetes incidence in some treatment windows targeting early insulitis. Thus, although a short and early intervention with 1,25-(OH)(2)D(3) (3-14 wk of age) reduced diabetes incidence (35 vs. 58%, P < or = 0.05), a late intervention (from 14 wk of age, when insulitis is present) failed to prevent disease. Of note, only early and long-term treatment (3-28 wk of age) prevented disease to a major extent (more than 30% decrease in diabetes incidence). We conclude that 1,25-(OH)(2)D(3) monotherapy is most effective in preventing diabetes in NOD mice when applied early. This beneficial effect of 1,25-(OH)(2)D(3) is associated with decreased chemokine and cytokine expression by the pancreatic islets.
Similar articles
- Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans.
Wolden-Kirk H, Rondas D, Bugliani M, Korf H, Van Lommel L, Brusgaard K, Christesen HT, Schuit F, Proost P, Masini M, Marchetti P, Eizirik DL, Overbergh L, Mathieu C. Wolden-Kirk H, et al. Endocrinology. 2014 Mar;155(3):736-47. doi: 10.1210/en.2013-1409. Epub 2014 Jan 1. Endocrinology. 2014. PMID: 24424042 - IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice.
Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. Cardozo AK, et al. Diabetologia. 2003 Feb;46(2):255-66. doi: 10.1007/s00125-002-1017-0. Epub 2003 Feb 12. Diabetologia. 2003. PMID: 12627325 - Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A.
Casteels KM, Mathieu C, Waer M, Valckx D, Overbergh L, Laureys JM, Bouillon R. Casteels KM, et al. Endocrinology. 1998 Jan;139(1):95-102. doi: 10.1210/endo.139.1.5641. Endocrinology. 1998. PMID: 9421403 - Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system.
Mathieu C, van Etten E, Decallonne B, Guilietti A, Gysemans C, Bouillon R, Overbergh L. Mathieu C, et al. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):449-52. doi: 10.1016/j.jsbmb.2004.03.014. J Steroid Biochem Mol Biol. 2004. PMID: 15225818 Review. - Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
Ammon HPT. Ammon HPT. Phytomedicine. 2019 Oct;63:153002. doi: 10.1016/j.phymed.2019.153002. Epub 2019 Jun 28. Phytomedicine. 2019. PMID: 31301539 Review.
Cited by
- Multifaceted Roles of Vitamin D for Diabetes: From Immunomodulatory Functions to Metabolic Regulations.
Park CY, Shin S, Han SN. Park CY, et al. Nutrients. 2024 Sep 20;16(18):3185. doi: 10.3390/nu16183185. Nutrients. 2024. PMID: 39339785 Free PMC article. Review. - Association between vitamin D status and cardiometabolic risk factors in adults with type 2 diabetes in Shenzhen, China.
Liu YJ, Duan JW, Lu DH, Zhang F, Liu HL. Liu YJ, et al. Front Endocrinol (Lausanne). 2024 Feb 14;15:1346605. doi: 10.3389/fendo.2024.1346605. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38419955 Free PMC article. - The Association Between Glycated Hemoglobin (HbA1c) Level and Vitamin D Level in Diabetes Mellitus Patients: A Cross-Sectional Study.
Alqahtani RM, Alsulami EF. Alqahtani RM, et al. Cureus. 2023 Oct 17;15(10):e47166. doi: 10.7759/cureus.47166. eCollection 2023 Oct. Cureus. 2023. PMID: 38022364 Free PMC article. - The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art.
Argano C, Mirarchi L, Amodeo S, Orlando V, Torres A, Corrao S. Argano C, et al. Int J Mol Sci. 2023 Oct 23;24(20):15485. doi: 10.3390/ijms242015485. Int J Mol Sci. 2023. PMID: 37895163 Free PMC article. Review. - Effects of vitamin D supplementation on cardiometabolic parameters among patients with metabolic syndrome: A systematic review and GRADE evidence synthesis of randomized controlled trials.
Aquino S, Cunha A, Gomes Lima J, Sena-Evangelista K, Gouveia Oliveira A, Cobucci RN, Fc Pedrosa L. Aquino S, et al. Heliyon. 2023 Oct 12;9(11):e20845. doi: 10.1016/j.heliyon.2023.e20845. eCollection 2023 Nov. Heliyon. 2023. PMID: 37885733 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases